Is erythropoietin effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase?
The authors concluded that erythropoietin is safe and effective in patients in chronic-phase CML who develop anemia with imatinib therapy.
Rapamycin protected against RIPF in a murine model. Rapamycin treatment reduced inflammatory cytokine expression, extracellular matrix production, and senescence in type II pneumocytes.